drugset / Trial / NCT06941077

A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants

NCT06941077

Phase 1 Completed 48 enrolled Incyte Corporation
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants.

Timeline

Start
2025-05-12
Primary completion
2025-06-03
Completion
2025-06-03

Drugs

EvaluationDrugModalityDoseRoute
Subject INCB057643 Small molecule Oral

Indications

No indication recorded.